What is the latest PCVX analyst rating from Jefferies?

Jefferies maintained a **Buy** on **Vaxcyte (PCVX)** on **March 10, 2026**, citing the adult PCV program as a driver of higher long-term valuation. No new price target was published in the note.

How did the market respond to the PCVX analyst rating?

The Jefferies note produced a modest market reaction of **0.22% ($0.13)** on the reported day. The market cap at the time was **$8,381,900,800**, indicating limited immediate price impact.

Does the Jefferies note include a PCVX price target?

Jefferies reiterated its Buy rating but did not disclose a new PCVX price target in the published StreetInsider summary of the note. Investors should look for full reports for any target updates.

How should investors use this PCVX analyst rating?

Treat the maintained Buy as a vote of confidence in Vaxcyte’s adult PCV program, but balance it with clinical timelines, regulatory risk, and portfolio sizing rules. The Meyka AI grade of **B** offers additional context.

Analyst Ratings

Jefferies Maintains Buy on Vaxcyte (PCVX) March 10, 2026

ByDanny Kontos March 11, 2026

Jefferies maintained its Buy rating on Vaxcyte, Inc. (PCVX) on March 10, 2026, marking a continued bullish stance in its coverage. This PCVX analyst rating note emphasized that the company’s adult pneumococcal conjugate vaccine program could support a materially higher long-term valuation. The firm reiterated conviction without publishing a new price target, while the stock moved 0.22% ($0.13) on the announcement.